EBR Systems Gains Priority Review Status for Wireless Heart Device in Australia
EBR Systems secures accelerated Australian regulatory pathway for wireless heart failure device
EBR Systems (ASX: EBR) has been granted Priority Review Determination by the Therapeutic Goods Administration (TGA) for its WiSE System, providing an accelerated pathway toward Australian market entry for the company’s wireless cardiac pacing device. The determination addresses a “high unmet clinical need” in heart failure patients and positions the company to complement its existing U.S. operations following FDA approval in April 2025.
The company lodged its TGA submission on 12 March 2026 and now intends to submit its application for inclusion on the Australian Register of Therapeutic Goods (ARTG) in the near term. ARTG inclusion is required before the device can be legally sold in Australia.
Australian market entry represents geographic revenue diversification beyond the U.S., reducing reliance on a single market during the company’s early commercialisation phase.
When big ASX news breaks, our subscribers know first
What is TGA Priority Review and why does it matter?
The TGA Priority Review pathway is an accelerated evaluation process for breakthrough medical devices that address life-threatening or seriously debilitating conditions where high unmet clinical need exists. Devices granted this designation receive faster regulatory assessment compared to the standard pathway.
The practical impact is a reduction in evaluation time from the standard 225 working days to approximately 150 working days, saving roughly 75 working days or approximately 3.5 months. This accelerated timeline applies once EBR submits its ARTG inclusion application.
| Review Type | Evaluation Period |
|---|---|
| Standard Review | 225 working days |
| Priority Review | ~150 working days |
ARTG inclusion serves as the regulatory gateway to legal sale in Australia. The priority designation does not guarantee approval but compresses the review timeline, potentially bringing Australian revenue generation several months forward compared to the standard pathway.
WiSE System targets patients failed by conventional therapy
The WiSE System is a wireless, leadless cardiac pacing device designed to stimulate the heart’s left ventricle in patients requiring Cardiac Resynchronisation Therapy (CRT). The device specifically targets heart failure patients who have failed to benefit from or cannot receive conventional lead-based CRT therapy.
The technology’s key differentiator is the elimination of coronary sinus leads, which have historically been a major source of complications in conventional CRT. The implant itself is roughly the size of a large grain of rice, representing a miniaturised approach to endocardial pacing.
Key WiSE System differentiators:
- Wireless technology – no leads required to pace the left ventricle
- Endocardial pacing – stimulation from inside the heart chamber rather than external surface
- Leadless design – eliminates coronary sinus lead complications
- Left ventricle targeting – focuses on the chamber critical for CRT effectiveness
The device targets an underserved patient population with limited alternatives, creating a defensible market niche rather than competing directly with established lead-based CRT devices. Patients who cannot receive conventional therapy currently have few options.
CEO outlines expansion strategy beyond U.S.
John McCutcheon, President & Chief Executive Officer
“Receiving Priority Review Determination from the TGA is an important step in expanding access to the WiSE System beyond the U.S. and reflects the potential of this technology to address a significant unmet need for heart failure patients in Australia. With FDA approval secured, early U.S. commercial momentum building and growing clinical validation, we believe WiSE is well positioned to offer a differentiated leadless CRT option for patients who cannot receive or do not respond to conventional lead-based therapy.”
Management has framed the Australian regulatory pathway as part of a broader international expansion strategy building on FDA approval and early U.S. commercial momentum. The CEO’s reference to “growing clinical validation” suggests the regulatory submission benefits from real-world U.S. experience post-approval.
The WiSE System is currently only available for sale in the U.S., making Australia the second major market target.
The next major ASX story will hit our subscribers first
Regulatory and commercial momentum builds for EBR
The TGA Priority Review Determination represents the latest in a series of regulatory and commercial milestones achieved over the past 12 months. The trajectory shows accelerating progress from FDA approval through to international market expansion.
Recent regulatory and commercial timeline:
- FDA approval – April 2025
- U.S. commercialisation commenced – early revenue generation underway
- TGA Priority Review submission – 12 March 2026
- TGA Priority Review Determination granted – 24 April 2026
- ARTG application – near term
Multiple regulatory and commercial catalysts in quick succession demonstrate execution capability and reduce single-market concentration risk. If Australian approval is secured, EBR would mark its second major market entry within approximately 18 months of FDA clearance.
The company’s announcement notes that the TGA determination builds on “strong recent momentum across EBR’s regulatory, commercial and clinical programs, including FDA approval, growing U.S. commercial activity and early revenue generation.”
Next steps and investor watchpoints
The immediate next catalyst is submission of the ARTG inclusion application, which EBR intends to lodge “in the near term” according to the announcement. Once submitted, the accelerated Priority Review pathway provides for an evaluation period of approximately 150 working days.
Investors should monitor for:
- ARTG inclusion application lodgement announcement
- TGA evaluation updates during the review period
- Final ARTG inclusion decision
ARTG inclusion would clear the regulatory path for Australian commercial launch, representing a concrete revenue expansion catalyst on a defined timeline. The compressed review period means market entry could occur meaningfully faster than under standard regulatory assessment, potentially accelerating the company’s geographic diversification strategy.
Get Breaking Healthcare News Before the Market Reacts
Join 20,000+ investors receiving FREE ASX healthcare alerts within minutes of release, complete with expert analysis. Click the “Free Alerts” button at Big News Blast to get market-moving announcements delivered straight to your inbox the moment they break.